UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 299

Sortiert nach

Special Issue "From Basic Science to Treatment Strategies: Personalized Cancer Therapy"

International journal of molecular sciences, 2024-02, Vol.25 (3), p.1435

2024

Volltextzugriff (PDF)

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

Critical reviews in oncology/hematology, 2020-07, Vol.151, p.102978-102978, Article 102978

2020

Volltextzugriff (PDF)

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2577-2584

2021

Volltextzugriff (PDF)

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

International journal of molecular sciences, 2024-01, Vol.25 (1), p.624

2024

Volltextzugriff (PDF)

Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer

Cancers, 2021-10, Vol.13 (20), p.5038

2021

Volltextzugriff (PDF)

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1415-1421

2013

Volltextzugriff (PDF)

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

International journal of molecular sciences, 2024-02, Vol.25 (4), p.2366

2024

Volltextzugriff (PDF)

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

Scientific reports, 2017-05, Vol.7 (1), p.1526-11, Article 1526

2017

Volltextzugriff (PDF)

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

BMC cancer, 2023-10, Vol.23 (1), p.1-1000, Article 1000

2023

Volltextzugriff (PDF)

Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards

Journal of clinical oncology, 2020-02, Vol.38 (6), p.633-644

2020

Volltextzugriff (PDF)

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1140-1145

2011

Volltextzugriff (PDF)

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Molecular cancer, 2024-04, Vol.23 (1), p.78-78, Article 78

2024

Volltextzugriff (PDF)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer

Frontiers in oncology, 2023-03, Vol.13, p.1108124

2023

Volltextzugriff (PDF)

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Cancers, 2024-03, Vol.16 (6), p.1150

2024

Volltextzugriff (PDF)

Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location

Oncology and therapy, 2020-06, Vol.8 (1), p.59-66

2020

Volltextzugriff (PDF)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

Translational oncology, 2023-10, Vol.36, p.101744-101744, Article 101744

2023

Volltextzugriff (PDF)

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Frontiers in oncology, 2023-08, Vol.13, p.1215524-1215524

2023

Volltextzugriff (PDF)

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy

JCO global oncology, 2020-06, Vol.6 (6), p.784-788

2020

Volltextzugriff (PDF)

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1647-1662

2021

Volltextzugriff (PDF)

Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines

Current oncology reports, 2014-09, Vol.16 (9), p.400-400, Article 400

2014

Volltextzugriff (PDF)

Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors

Frontiers in oncology, 2021-10, Vol.11, p.752918-752918

2021

Volltextzugriff (PDF)

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-11, Vol.24 (31), p.5025-5033

2006

Volltextzugriff (PDF)

1 – 25 von 299

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(260)
Mit Volltextzugriff
(265)

Publikationsform

Artikel
(292)
Berichte
(7)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(135)
Oncology
(99)
Humans
(98)
Male
(38)
Lung Neoplasms - Drug Therapy
(37)
Female
(36)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(34)
Lung Cancer
(34)
Middle Aged
(28)
Aged
(25)
Antineoplastic Agents - Therapeutic Use
(24)
Tumors
(24)
Adult
(23)
Lung Neoplasms - Pathology
(23)
Biological And Medical Sciences
(22)
Cancer
(22)
Respiratory System
(22)
Medical Sciences
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Special Issue "From Basic Science to Treatment Strategies: Personalized Cancer Therapy"

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America

Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines

Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

Suchergebnisse filtern